Male sex was associated with higher age-adjusted mortality from concurrent ischemic heart disease and lung cancer than female sex (decreasing from 20.3 to 10.6 vs 6.8 to 4.6 per 100,000).
Observational
Between 1999 and 2023, mortality from concurrent ischemic heart disease and lung cancer decreased significantly in the US, though males and Non-Hispanic Black individuals continued to experience a disproportionate disease burden.
p-value: p=<0.05
11163 Background: Despite improvement in lung cancer prevention, early diagnosis & management, Ischemic heart disease (IHD) has become a major concurrent cause of mortality in lung cancer. Population level evidence on long term deaths due to IHD & lung cancer especially across sex & racial groups are lacking. Identification of these trends is necessary for cardio-oncology risk stratification & promote equitable survivorship care. Methods: We used the CDC WONDER Online Database to obtain mortality data for IHD & Lung Cancer from 1999-2023 from patients aged 45-85 & above. We used current final multiple cause of death data from 1999-2020 & 2018-2023. We used ICD-10 codes I20-I25 for IHD & C33-34 for Lung cancer. Data were stratified by Race (Non-Hispanic NH American Indian or Alaska Native, NH Asian or Pacific Islander, NH Black or African American, NH White, Hispanic or Latino), sex (male & female) and age groups (45-85+). We calculated age-adjusted mortality rates (AAMR) per 100,000 population based on the 2000 US standard population. Temporal mortality trends were analyzed using Joinpoint regression. (P < 0.05). Results: From 1999-2023, AAMR from lung cancer & IHD decreased in most demographic groups. Males had higher AAMR than females, with mortality decreasing from 20.3 to 10.6 per 100,000, compared with a decline from 6.8 to 4.6 per 100,000 among females. Joinpoint regression identified substantial reduction among males from 1999-2010 (annual percent change APC −2.35%, p < 0.05) & 2010-2016 (APC −5.45%, p < 0.05), followed by stabilization. Among females, declines were observed from 2005-2012 (APC −2.76%, p < 0.05) & 2012-2015 (APC −7.35%, p < 0.05), with a nonsignificant plateau thereafter. NH Black exhibited higher AAMRs despite significant declines from 2005-2018 (APC −4.11%, p < 0.05). NH White showed persistent declines from 1999-2017, followed by a marginal increase during 2017-2021. Hispanic & Asian or Pacific Islander individuals maintained the lowest AAMRs, with decreasing trends & brief late-2010s increases in select subgroups, while American Indian or Alaska Native individuals exhibited greater year-to-year variability without statistically significant joinpoints. Conclusions: During 1999-2023, mortality from IHD & lung cancer decreased significantly in the US. Males & NH Black experienced a major disease burden. Recent improvement in death trends among the select patient population showed appropriate cardiovascular risk management in survivors with lung cancer. This analysis highlighted the importance of cardio-oncology care models & precision-guided, equity-driven interventions to decrease cardiovascular mortality among patients with lung cancer.
KC et al. (Wed,) conducted a observational in Ischemic heart disease and lung cancer. Male sex was associated with higher age-adjusted mortality from concurrent ischemic heart disease and lung cancer than female sex (decreasing from 20.3 to 10.6 vs 6.8 to 4.6 per 100,000).